Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer by Strand, Fredrik et al.
  
 
 
 
 
 
 
 
 
 
 
 
This is the peer reviewed version of the following article Int J 
Cancer. 2017 Jan 1;140(1):34-40. Epub 2016 Sep 24., which 
has been published in final form at 
http://dx.doi.org/10.1002/ijc.30427. 
This article may be used for non-commercial purposes in 
accordance with Wiley Terms and Conditions for Self-
Archiving. 
 
Longitudinal fluctuation in mammographic percent 
density differentiates between interval and screen-
detected breast cancer.  Int J Cancer. 2017 Jan 
1;140(1):34-40. Epub 2016 Sep 24. 
 
 
Strand, Fredrik; Humphreys, Keith; Eriksson, Mikael; Li, 
Jingmei; Andersson, Therese ML; Törnberg, Sven; 
Azavedo, Edward; Shepherd, John; Hall, Per; Czene, 
Kamila 
 
DOI: http://dx.doi.org/10.1002/ijc.30427 
 
Access to the published version may require subscription. 
Published with permission from: Wiley 
 
 
1 
 
Title: Longitudinal fluctuation in mammographic percent density differentiates between interval 
and screen-detected breast cancer 
 
Authors and e-mail addresses: Fredrik Strand*1,2(fredrik.strand@ki.se), Keith Humphreys1,3 
(keith.humphreys@ki.se), Mikael Eriksson1 (mikael.eriksson@ki.se),  Jingmei Li1,4 
(jingmei.li@ki.se), Therese ML Andersson1 (therese.m-l.andersson@ki.se), Sven Törnberg5 
(sven.tornberg@sll.se), Edward Azavedo6,7 (edward.azavedo@ki.se), John Shepherd8 
(john.shepherd@ucsf.edu),  Per Hall1 (per.hall@ki.se), Kamila Czene1 (kamila.czene@ki.se)  
Author affiliations (1-8): 
1) Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 
Sweden 
2) Department of Diagnostic Radiology, Karolinska University Hospital, Stockholm, Sweden 
3) Swedish eScience Research Centre (SeRC), Karolinska Institutet, Stockholm, Sweden 
4) Genome Institute of Singapore, Singapore, Singapore. 
5) Department of Cancer Screening, Stockholm-Gotland Regional Cancer 
Centre, Stockholm, Sweden 
6) Department of Diagnostic Radiology, Karolinska Institutet, Stockholm, Sweden 
7) Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden 
8) Department of Radiology and Biomedical Imaging, UCSF School of Medicine, University of 
California, San Francisco, California, United States 
Corresponding author (*): Fredrik Strand 
Address: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, P.O. Box 
281, SE-171 77, Stockholm, Sweden 
E-mail: fredrik.strand@ki.se 
Telephone: +46 8 52482363 
Fax: +46 8314975 
2 
 
Novelty & Impact Statements  
Interval breast cancers are more aggressive and are associated with a higher mortality than 
screen-detected cancers. Mammographic percent density is one of few known risk factors and 
can be automatically calculated based on screening mammograms. The authors of this study 
estimated long-term trends of mammographic density for each participating woman. They found 
that a measure of the fluctuation around the individual long-term trend was associated with an 
increased proportion of interval cancer. This is a novel and interesting finding that may enable 
us to better identify women at elevated risk - after validation in a screening population. 
Abstract 
Interval breast cancer (IC) has a more aggressive phenotype and higher mortality than screen-
detected cancer (SDC). In this case-case study, we investigated whether the size of longitudinal 
fluctuations in mammographic percent density (PD fluctuation) was associated with the ratio of 
IC vs. SDC among screened women with breast cancer. The primary study population consisted 
of 1,414 postmenopausal breast cancer cases, and the validation population of 1,241 cases. We 
calculated PD fluctuation as the quadratic mean of deviations between actual PD and the long-
term trend estimated by a mixed effects model. In a logistic regression model we examined the 
association between PD fluctuation and interval vs. screen-detected cancer including 
adjustments for PD at last screening, age at diagnosis, BMI and hormone replacement therapy. 
All statistical tests were two-sided. There were 385 IC and 1029 SDC in the primary study 
population, with PD fluctuations of 0.44 and 0.41 respectively (p=0.0309). After adjustments, PD 
fluctuation was associated with an increased ratio of IC vs. SDC, with an estimated per-standard 
deviation odds ratio of 1.17 (95% CI = 1.03 to 1.33), compared to 1.19 (95% CI = 1.04 to1.38) in 
the validation population. In screened women with breast cancer, high fluctuation in 
mammographic percent density was associated with an increased ratio of IC vs. SDC. Whether 
this is entirely related to a reduced mammographic detectability or to a biological phenotype 
promoting faster tumor growth remains to be elucidated.  
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INTRODUCTION 
Interval breast cancer (IC) has a more aggressive phenotype and higher mortality than screen-
detected cancer1-6. IC is defined as breast cancer that is detected after a negative screen but 
before the next regular visit or end of a normal screening interval - which in Sweden has a length 
of 18 to 24 months depending on age and county. In a review of 10 different studies, most of 
them Scandinavian, the proportion of ICs was 22 to 37 % in the regularly screened women7.  
 
IC has been shown to be associated with mammographic density 1, 8, 9, which is usually 
expressed as a percentage of the total breast area and called ‘percent density’ (PD). A higher 
PD means that there is more dense tissue in the breast that could potentially mask an incident 
tumor10, 11. The potential masking problem decreases as the woman ages due to a long-term 
trend of decreasing PD12. 
 
To minimize the risk that a subtle malignant change in the mammogram is missed it is good 
practice for radiologists to compare the current image with previous ones. We hypothesized that 
high fluctuation in density reflects large variations in mammographic appearance, which would 
increase the likelihood that a subtle malignant change passes unnoticed by the screening 
radiologist, i.e. that high fluctuation reduces mammographic detectability. 
 
Our aim was to study a case-only cohort to examine whether a large fluctuation in PD between 
pre-diagnostic mammograms would be associated with an increased ratio of IC vs. SDC once a 
tumor has been initiated. PD fluctuation was calculated as a summary measure of the deviations 
between the actual PD measurements and the estimated individual long-term trend.  
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METHODS 
Study Populations 
We analyzed postmenopausal breast cancer cases in the Libro-1 cohort, which consists of 
women in the Stockholm-Gotland region diagnosed with breast cancer from 2001 to 20089, 13. All 
individuals were identified through the Stockholm-Gotland Regional Breast Cancer Register. The 
Libro-1 cohort was established by inviting all women in Stockholm with breast cancer who were 
younger than age 80 years at diagnosis and diagnosed between 2001 and 2008 to participate. 
The overall response rate was 62%. In our study, we included women diagnosed with incident 
unilateral invasive breast cancer without any other previous cancer with the exception of non-
melanoma skin cancer. We only included women post-menopausal at diagnosis with at least 
one pre-diagnostic mammogram of the contralateral breast, in the mediolateral oblique view, 
without a prior benign breast surgery, and where information on mode of detection was 
available. SDC, screen-detected breast cancer, was defined as a breast cancer diagnosis made 
after a positive screen finding but before the next visit or end of a normal screening interval. IC, 
interval breast cancer, was defined as a breast cancer diagnosis made after a negative screen 
but before the next regular visit or end of a normal screening interval. Symptomatic cases 
without previous screening were not included. During the study period, the overall screening 
participation rate in the Stockholm county was 70%, the recall rate was 3%, and the detection 
rate was 0.5% as described by Lind et al14. 
 
To validate our findings, we analyzed a second cohort of patients with post-menopausal breast 
cancer, the Cahres cohort1. It contained incident breast cancer cases diagnosed from October 1, 
1993, to March 15,1995, and reported to any of the six Swedish Regional Cancer Registries. 
From this cohort, we were able to include 1,241 cases, of which 242 were IC and 999 were SDC 
as a validation population. The same inclusion and exclusion criteria were applied as for the 
primary study population. The reason for adding a validation cohort was to ensure that we had 
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not introduced overfitting through preliminary examination of alternative fluctuation measures in 
the primary study population. 
 
Data collection 
Data collection was performed similarly for the primary and the validation population. Information 
about BMI, HRT use, and other socio-demographic, anthropometric, hormonal, and lifestyle 
factors was obtained through questionnaires. Use of HRT was classified as ‘current’ or ‘non-
current’ referring to the time-point of diagnosis. Data on age at menopause was only collected in 
the validation population. 
 
We sought to retrieve all mammograms for the eligible women by using the Swedish national 
registration numbers given to all Swedish citizens at birth. We collected mammograms by 
contacting local mammography units as well as the national Swedish medical image repository 
in Vilhelmina, Sweden. In the study population there were 172 women with one mammogram, 
178 women with two mammograms, and 1064 women with three or more mammograms. In total 
there were 5964 mammogram images. We did not have data on examination characteristics 
such as the brand of the mammography equipment or compression pressure applied by the 
mammography nurse. 
 
All mammograms were analog film mammograms that were digitized using an Array 2905HD 
Laser Film Digitizer, which covers a range of 0 to 4.7 optical densities. The density resolution 
was set at 12-bit dynamic range. To avoid image acquisition bias related to suspected diagnosis 
we included only mammograms up until 60 days before the registered date of diagnosis. An 
automated method was used for PD measurement, which has previously been described in 
detail15. Briefly, the method attempts to mimic the gold standard PD measurement method 
Cumulus16, which uses an automated thresholding procedure to obtain PD readings. For PD 
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measurement we used the mediolateral oblique view mammograms of the breast contralateral to 
the breast with the tumor. Using the contralateral image ensured that there could be no early 
tumor included in the PD measurements.  
Statistical analysis 
We used all available pre-diagnostic mammograms to estimate PD fluctuation by comparing the 
actual PD at each mammography with the PD predicted through modelling a smooth curve over 
time for each individual. The individual smooth PD curves were obtained by fitting a mixed 
effects regression model with PD as the outcome and age at mammography as the predictor. In 
all analyses, PD-based measures were square-root-transformed before modelling. We allowed 
PD to be a non-linear function of age by adding two cubic spline segments. Two segments were 
chosen since adding a third one resulted in non-significant beta coefficients. We allowed random 
effects for slope and intercept, with an unstructured covariance matrix. For each individual, at 
each mammography, we calculated the difference between the actual PD measure and the 
value predicted by the mixed effects model. The predicted values of the random effect depend 
upon the (unknown) covariance among the PD values, following the approach in section 8.6 in 
Fitzmaurice et al17. A single measure of PD fluctuation per individual was then calculated as the 
quadratic mean, or root-mean-square, of these differences; by using the quadratic mean rather 
than the arithmetic mean we ensured that deviations in opposite directions would not cancel 
each other out. Thus, the PD fluctuation measure is the average size, independent of the 
direction, of fluctuations away from the long-term PD trend. 
 
We used logistic regression models to estimate the associations between IC/SDC status and PD 
fluctuation; first crude, then adjusted for PD at last pre-diagnostic examination, and finally a 
multiple adjusted model including PD fluctuation, pre-diagnostic PD, age at diagnosis, BMI and 
HRT use at diagnosis. We did not include family history of breast cancer, age at menarche or 
parity as covariates in our final model since they did not show any significant association with 
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IC/SDC status. Effect estimates are presented as odds ratios. For validation, we estimated the 
fully adjusted logistic regression model in an independent breast cancer cohort. Inherent to the 
mixed effects model used in the first stage of our analysis, the estimated fluctuation of a woman 
with less than three mammograms is largely based on data from the rest of the population. We 
examined how data from these women affected the estimated association between PD 
fluctuation through re-estimating the logistic regression model after exclusion of these 
individuals (those with less than three mammograms) in our primary study population. In order to 
illustrate the impact of having high or low PD fluctuation, we performed the fully adjusted logistic 
regression categorizing the continuous covariate PD fluctuation into quartiles. We then 
estimated the proportion of IC of the sum of IC and SDC breast cancer cases for each quartile of 
PD fluctuation. This was done holding the values of all other covariates fixed, reflecting a 
“typical” woman (age at diagnosis and BMI equal to the population mean and HRT status equal 
to ‘non-current’). All statistical tests were two sided. 
 
Our two-stage model implies that the uncertainty of the parameter estimates in the first stage 
model is not carried over to the estimation of the second stage model (i.e., predicted PD 
fluctuation is treated as a fixed variable at the second stage). Therefore, we also estimated a 
single-stage mixed effects model in the primary population, with PD as the outcome. In this 
model we allowed the variance of the random effect for the constant to vary according to IC/SDC 
status and included a fixed effect for IC/SDC status (as well as included fixed and random 
effects for age at mammography). 
 
Informed consent and ethical approval  
All participants provided written informed consent, and the study had approval from the ethical 
review board at Karolinska Institutet, Stockholm, Sweden. 
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RESULTS 
In our primary study population we included 1414 women, 385 IC cases and 1029 SDC cases. 
The IC cases had a significantly lower age at diagnosis, a lower BMI, and were more frequently 
HRT users than were the SDC cases. The tumors of the IC cases were larger and had more 
often lymph node metastasis than the SDC cases [Table 1]. The average number of 
mammograms per woman was 4.3 for IC cases and 4.2 or SDC cases. 
 
To illustrate the fact that a simple measure of variability (e.g., the standard deviation) would not 
differentiate between fluctuations and long-term trend we plotted the PD measurements over 
time for the women with the highest vs. the lowest of the raw measurements [Supplementary 
Figure 1]. Although there were some women in the high standard deviation group who had high 
fluctuations, and little long-term change, there were many women with high long-term change 
but relatively small fluctuations as well. This convinced us that it would be appropriate to use the 
proposed two-stage analysis, where the first stage involved estimating a mixed effects model 
[Supplementary Table 1]. As an illustration of how the individual long-term trend was positioned, 
we extracted observed PD measures and the corresponding model predicted smooth curve for 
two individuals, both with approximately 25 % PD at age 60 – one woman with large PD 
fluctuation and subsequent IC, and one woman with small PD fluctuation and subsequent SDC 
[Figure 1]. This figure illustrates that even though there is a long-term trend of declining PD, 
there is substantial fluctuation around that long-term trend. 
 
We found that the PD fluctuation, the quadratic mean of deviations from the estimated long-term 
trend, was significantly higher for IC than for SDC (0.44 vs. 0.41, p=0.0309) [Table 2]. 
Supplementary Figure 2 shows the distributions of PD fluctuation for IC and SDC cases. Pre-
diagnostic PD was significantly higher for IC than for SDC (25.5% vs. 20.3%, p<0.0001). There 
were no significant differences between IC and SDC cases regarding the following potential 
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confounders: total number of mammograms per person, average time between mammograms, 
mean age at mammography or time from first to last mammogram. 
  
From fitting a logistic regression model with IC/SDC status as the outcome and (the model-
based estimate of) PD fluctuation as the exposure we obtained an estimate of per-standard 
deviation OR of 1.14 (95% CI = 1.01 to 1.28) without adjustment [Table 3]. In the multiple 
adjusted model including last pre-diagnostic PD, age at diagnosis, BMI and HRT use at 
diagnosis as covariates, the OR was 1.17 (95% CI = 1.03 to 1.33) in the primary study 
population, and 1.19 (95% CI = 1.04 to 1.38) in the validation population. Exclusion of women 
with less than three mammograms, in the primary population, decreased the estimated OR in 
the multiple adjusted model slightly to 1.14 and widened the confidence interval (95% CI = 0.97 
to 1.34). To examine the assumption of linearity underlying the OR per standard-deviation 
estimates, we added a quadratic term of the PD fluctuation variable. This term was not 
significantly associated with the outcome of the model, and we conclude that there is no strong 
evidence for such non-linearity. Combining the primary and the validation populations in a single 
logistic regression model and adding a categorical cohort identification covariate, we estimated 
the OR to the 1.16 (95% CI = 1.05 to 1.27). Adjusting for menopause transition during the time 
period of measurements changed the OR in the validation population to 1.17 (95% CI = 1.01 to 
1.35), and the menopause transition variable was not significant in the model. In the primary 
study population data on age at menopause was not collected. 
 
In Figure 2, we illustrate how the proportion of IC, out of the total of IC and SDC, differs between 
quartiles of PD Fluctuation in the primary study population. Setting all other covariates to the 
population average, we estimated that the proportion of IC was 19 percent in the lowest vs. 27 
percent in the highest quartile of PD fluctuations. 
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The alternative single-stage modeling of PD over time including IC/SDC status as a covariate, 
showed that the additional variability in PD for individuals with IC (as opposed to SDC) status 
was significant (0.0228; 95% CI = 0.004 to 0.139), supporting the existence of differences in 
fluctuations between IC and SDC cases..  
DISCUSSION 
We have demonstrated that high longitudinal fluctuation in mammographic percent density of 
benign breast tissue is associated with an increased ratio of IC compared to SDC. The 
association was validated in an independent cohort, and was independent of last pre-diagnostic 
PD, age at diagnosis, BMI, and use of HRT. The proportion of interval cancer, out of interval and 
screen-detected together, increased from 19 to 27 percent between the lowest and highest 
quartile of mammographic density fluctuations. 
 
In the first stage of our analysis, we applied mixed effects modeling of mammographic density 
as a function of age at mammography to estimate individual long-term trends. Unfortunately, 
such a complex approach is called for since simpler ones based on measuring variation without 
removing the underlying trend would not capture the relevant information for testing our 
hypothesis. Using splines when modeling density as a function of age at mammography allowed 
for a more rapid decrease in density around menopause in the population. In the second stage 
logistic regression we determined that there was an association between density fluctuations 
and the ratio of interval vs. screen-detected cancer also after taking age at diagnosis, BMI and 
use of HRT into account. In the validation population we were able to determine that this 
association did not materially change after taking into consideration whether a woman had a 
menopause transition during the period of sequential mammograms. Exclusion of women with 
less than 3 mammograms weakened the identified association slightly, and decreased the 
precision of the analysis. 
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We hypothesize that large fluctuations of mammographic density can result in reduced 
radiological screening detectability and consequently in an increased ratio of IC compared to 
SDC. In addition, large fluctuation might also be a marker of an intramammary environment 
promoting faster-growing tumors. Weekly fluctuations in breast tissue, in both pre- and 
postmenopausal women, have been demonstrated in a previous MRI-based study 18. There is 
some evidence from a mammography study that tissue fluctuations might be correlated with 
phases in the menstrual cycle 19. There have not been any studies explaining the basis for 
potential tissue fluctuations among post-menopausal women. The total density fluctuation 
observed in this study would be a combination of true tissue fluctuations and artificial 
fluctuations caused by differences in examination technique and mammography nurse practices 
between sequential mammograms. Our original hypothesis was based on fluctuations 
representing variations between sequential mammograms making it more difficult for the 
screening radiologist to discern a subtle malignant change. Therefore, the total fluctuation 
between images should be the most relevant measure. However, in future research, it would be 
of interest to control for differences in examination characteristics between examinations. That 
would enable us to better understand whether fluctuations may be related to some biological 
characteristics that are associated with faster-growing tumors or less visible histological 
subtypes.   
 
One strength of our study is that we were able to collect a large number of pre-diagnostic 
mammograms for most of the women. Another strength is that we had extensive information on 
established IC determinants, with a low rate of missing information, allowing appropriate 
adjustments for confounders. A final strength is that we were able to validate our main finding in 
an independent breast cancer cohort. A limitation of the study is that is based on a case-only 
cohort, from which conclusions for changing screening policy cannot be drawn. Another 
limitation is that the age of menopause was only known in the validation population. A potential 
modeling limitation of the two-stage approach in our study is that the uncertainty in estimating 
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PD fluctuation at the first stage is not carried over to the second stage. Nevertheless, both this 
model and the single-stage model resulted in the same conclusion regarding a difference in PD 
fluctuation between IC and SDC cases. 
 
In conclusion, based on a case-only cohort, large longitudinal fluctuation in mammographic 
percent density increases the ratio of interval compared to screen-detected breast cancer. 
Whether this is entirely related to a reduced mammographic detectability or also to a biological 
phenotype promoting faster tumor growth remains to be elucidated. The association between 
interval cancer and density fluctuations should be further assessed in a screening cohort 
including healthy women before considered as a potential marker of elevated risk of interval 
cancer and thus potentially applied to direct additional screening resources.  
 
Ethics, consent and permissions 
All participants provided written informed consent to participate, and the studies had approval 
from the ethics committee at Karolinska Institutet, Stockholm, Sweden (Dnr 2009/254-31/4). 
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Table	1	Patient	characteristics
Study	population	(n=1,414)
IC	(n=385) SDC	(n=1,029) p	value Missing
n	(%)	or	mean n	(%)	or	mean data
Age	at	diagnosis 61.2 61.7 0.0417 0%
BMI 24.9 25.8 0.0004 1.3%
Oral	contraceptive	use 0.863 1.0%
No 290 (77%) 779 (76%)
Yes 89 (23%) 245 (24%)
HRT	use	at	diagnosis <0.001 2.4%
No 287 (76%) 852 (85%)
Yes 89 (24%) 152 (15%)
First-degree	relative	with	breast	cancer 0.092 6.1%
No 278 (77%) 781 (81%)
Yes 85 (23%) 186 (19%)
Tumor	size,	mm 19.8 15.6 <0.0001 1.3%
Lymph	node	metastasis <0.0001 7.8%
Negative 332 (87%) 972 (95%)
Positive 50 (13%) 56 (5%)
IC	=	Interval	breast	cancer
SDC	=	Screen-detected	breast	cancer
p-values	for	difference	between	the	IC	and	SDC	group	were	calculated	by	two-sided	t-test	for
continuous	variables;	and	by	chi	square	tests	for	categorical	variables.  
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Table	2	Mammographic	characteristics
Study	population	(n=1,414)
IC	(n=385) SDC	(n=1032) p	value
mean (SD) mean (SD)
PD	fluctuation,	RMS 0.44 (0.22) 0.41 (0.22) 0.0309
PD	last	pre-diagnostic,	percent 26 (16) 20 (13) <0.0001
Time	between	mammogram	rounds,	years 1.64 (1.14) 1.62 (1.05) 0.6939
Age	at	mammography,	years 55.6 (4.80) 55.4 (4.17) 0.3348
Time	from	first	to	last	mammogram,	years 7.74 (5.53) 7.47 (5.20) 0.4054
Number	of	mammograms n (proportion) n (proportion) 0.681
1 47 (12%) 125 (12%)
2 50 (13%) 128 (12%)
3	or	more 288 (75%) 776 (75%)
IC	=	Interval	breast	cancer
SDC	=	Screen-detected	breast	cancer
PD	fluctuation	=	Measure	of	deviations	from	the	long-term	trend	of	PD
RMS	=	Root-mean-square
SD=standard	deviation
p-values	for	difference	between	the	IC	and	SDC	group	were	calculated	by	two-sided	t-test
In	all	tests,	PD-based	measures	were	square-root-transformed  
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Table	3	Associations	between	PD	fluctuation	and	IC	vs	SDC	status
Primary	cohort	(Libro-1) Validation	cohort	(Cahres)
Adjustments Odds	ratio	(95%	C.I.) Odds	ratio	(95%	C.I.)
Crude 1.14	(1.01	to	1.28) 1.22	(1.06	to	1.40)
PD	adjusted 1.14	(1.02	to	1.29) 1.18	(1.03	to	1.36)
Multiple	adjusted 1.17	(1.03	to	1.33) 1.19	(1.04	to	1.38)
PD	fluctuation	=	RMS	measure	of	deviation,	including	all	prediagnostic	mammograms,
compared	to	the	individual	long-term	trend	of	PD
Odds	Ratios	were	estimated	by	logistic	regression	with	IC	vs	SDC	status	as	outcome
Covariates	in	the	'Multiple	adjusted'	model	are	PD,	age	at	diagnosis,	BMI	and	HRT	use
IC	=	Interval	breast	cancer
SDC	=	Screen-detected	breast	cancer
In	all	tests	PD-based	covariates	were	square-root-transformed
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Supplementary Table 1. Parameter estimates from the (stage 1) mixed effects model in 
the primary population. 
 
Mixed effects model 
sqrt(PD) = β0 + β1×age_spline1 + β2×age_spline2 + ui0 + ui1×age_spline1 + ui2×age_spline2 + eij 
 
Parameter estimates in primary study population 
Fixed effects parameters 
β0 : 6.58 (95% CI: 6.43 to 6.74) 
β1 : -0.00979 (95% CI: -0.0107 to -0.0089) 
β2 : 0.00166 (95% CI: 0.00046 to 0.00286) 
 
Random effects parameters 
σ2(ui0) : 2.101 (95% CI: 1.673 to 2.640) 
σ2(ui1) : 0.0000447 (95% CI: 0.0000313 to 0.0000638) 
σ2(ui2) : 0.0000371 (95% CI: 0.0000174 to 0.0000791) 
σ(ui0 , ui1) : -0.00520 (95% CI: -0.00769 to -0.002712) 
σ(ui0 , ui2) : -0.000976 (95% CI: -0.00200 to 0.00396) 
σ(ui1 , ui2) : -0.000027 (95% CI: -0.000046 to -0.000008) 
 
Residual 
σ2(eij) : 0.378 (95% CI: 0.360 to 0.396) 
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